Factors associated with non-attendance at scheduled infant follow-up visits in an observational cohort of HIV-exposed infants in South Africa, 2012-2014.


Journal

BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551

Informations de publication

Date de publication:
16 Sep 2019
Historique:
entrez: 19 9 2019
pubmed: 19 9 2019
medline: 18 12 2019
Statut: epublish

Résumé

Since 2001 the South African guidelines to improve child health and prevent vertical HIV transmission recommended frequent infant follow-up with HIV testing at 18 months postpartum. We sought to understand non-attendance at scheduled follow-up study visits up to 18 months, and for the 18-month infant HIV test amongst a nationally representative sample of HIV exposed uninfected (HEU) infants from a high HIV-prevalence African setting. Secondary analysis of data drawn from a nationally representative observational cohort study (conducted during October 2012 to September 2014) of HEU infants and their primary caregivers was undertaken. Participants were eligible (N = 2650) if they were 4-8 weeks old and HEU at enrolment. All enrolled infants were followed up every 3 months up to 18 months. Each follow-up visit was scheduled to coincide with each child's routine health visit, where possible. The denominator at each time point comprised HEU infants who were alive and HIV-free at the previous visit. We assessed baseline maternal and early HIV care characteristics associated with the frequency of 'Missed visits' (MV-frequency), using a negative binomial regression model adjusting for the follow-up time in the study, and associated with missed visits at 18 months (18-month MV) using a logistic regression model. The proportion of eligible infants with MV was lowest at 3 months (32.7%) and 18 months (31.0%) and highest at 12 months (37.6%). HIV-positive mothers not on triple antiretroviral therapy (ART) by 6-weeks postpartum had a significantly increased occurrence rate of 'MV-frequency' (adjusted incidence rate ratio, 1.2 (95% confidence interval (CI), 1.1-1.4), p < 0.0001). Compared to those mothers with ART, these mothers also increased the risk of '18-month-MV' (adjusted odds ratio, 1.3 (CI, 1.1-1.6), p = 0.006). Unknown infant nevirapine-intake status increased the rate of 'MV-frequency' (p = 0.02). Mothers > 24 years had a significantly reduced rate of 'MV-frequency' (p ≤ 0.01) and risk of '18-month-MV' (p < 0.01) compared to younger women. Shorter travel time to health facility lowered the occurrence of 'MV-frequency' (p ≤ 0.004). Late initiation of maternal ART and infant prophylaxis under the Option- A policy and extended travel time to clinics (measured at 6 weeks postpartum), contributed to higher postnatal MV rates. Mothers older than 24 years had lower MV rates. Targeted interventions may be needed during the current PMTCT Option B+ (lifelong ART to pregnant and lactating women at HIV diagnosis) to circumvent these risk factors and reduce missed visits during HIV-care.

Sections du résumé

BACKGROUND BACKGROUND
Since 2001 the South African guidelines to improve child health and prevent vertical HIV transmission recommended frequent infant follow-up with HIV testing at 18 months postpartum. We sought to understand non-attendance at scheduled follow-up study visits up to 18 months, and for the 18-month infant HIV test amongst a nationally representative sample of HIV exposed uninfected (HEU) infants from a high HIV-prevalence African setting.
METHODS METHODS
Secondary analysis of data drawn from a nationally representative observational cohort study (conducted during October 2012 to September 2014) of HEU infants and their primary caregivers was undertaken. Participants were eligible (N = 2650) if they were 4-8 weeks old and HEU at enrolment. All enrolled infants were followed up every 3 months up to 18 months. Each follow-up visit was scheduled to coincide with each child's routine health visit, where possible. The denominator at each time point comprised HEU infants who were alive and HIV-free at the previous visit. We assessed baseline maternal and early HIV care characteristics associated with the frequency of 'Missed visits' (MV-frequency), using a negative binomial regression model adjusting for the follow-up time in the study, and associated with missed visits at 18 months (18-month MV) using a logistic regression model.
RESULTS RESULTS
The proportion of eligible infants with MV was lowest at 3 months (32.7%) and 18 months (31.0%) and highest at 12 months (37.6%). HIV-positive mothers not on triple antiretroviral therapy (ART) by 6-weeks postpartum had a significantly increased occurrence rate of 'MV-frequency' (adjusted incidence rate ratio, 1.2 (95% confidence interval (CI), 1.1-1.4), p < 0.0001). Compared to those mothers with ART, these mothers also increased the risk of '18-month-MV' (adjusted odds ratio, 1.3 (CI, 1.1-1.6), p = 0.006). Unknown infant nevirapine-intake status increased the rate of 'MV-frequency' (p = 0.02). Mothers > 24 years had a significantly reduced rate of 'MV-frequency' (p ≤ 0.01) and risk of '18-month-MV' (p < 0.01) compared to younger women. Shorter travel time to health facility lowered the occurrence of 'MV-frequency' (p ≤ 0.004).
CONCLUSION CONCLUSIONS
Late initiation of maternal ART and infant prophylaxis under the Option- A policy and extended travel time to clinics (measured at 6 weeks postpartum), contributed to higher postnatal MV rates. Mothers older than 24 years had lower MV rates. Targeted interventions may be needed during the current PMTCT Option B+ (lifelong ART to pregnant and lactating women at HIV diagnosis) to circumvent these risk factors and reduce missed visits during HIV-care.

Identifiants

pubmed: 31526372
doi: 10.1186/s12879-019-4340-5
pii: 10.1186/s12879-019-4340-5
pmc: PMC6745773
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

788

Références

AIDS. 2008 Aug 20;22(13):1679-81
pubmed: 18670232
Curr HIV/AIDS Rep. 2010 Nov;7(4):234-44
pubmed: 20820972
Int J Womens Health. 2011;3:359-66
pubmed: 22140322
BMC Int Health Hum Rights. 2012 Aug 10;12:13
pubmed: 22883969
J Int AIDS Soc. 2013 Jul 19;16:18588
pubmed: 23870277
ISRN AIDS. 2012 Jul 31;2012:589817
pubmed: 24052879
AIDS. 2013 Nov 13;27(17):2787-97
pubmed: 24056068
PLoS One. 2013 Sep 20;8(9):e74568
pubmed: 24073215
J Acquir Immune Defic Syndr. 2014 Apr 15;65(5):e170-8
pubmed: 24759066
Trop Med Int Health. 2014 Nov;19(11):1360-6
pubmed: 25087778
J Epidemiol Community Health. 2015 Mar;69(3):240-8
pubmed: 25371480
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):e26-32
pubmed: 25469521
J Acquir Immune Defic Syndr. 2015 Jan 1;68(1):62-72
pubmed: 25501345
BMC Health Serv Res. 2014 Dec 19;14:646
pubmed: 25523349
BMC Public Health. 2015 Mar 07;15:228
pubmed: 25886161
S Afr Med J. 2014 Dec;104(12):874-80
pubmed: 26042271
Pediatr Res. 2016 Jun;79(6):838-45
pubmed: 26882367
J Int AIDS Soc. 2016 Mar 21;19(1):20662
pubmed: 27005750
J Glob Health. 2016 Dec;6(2):020405
pubmed: 27698999

Auteurs

Nobubelo Kwanele Ngandu (NK)

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa. nobubelo.ngandu@mrc.ac.za.

Debra Jackson (D)

UNICEF, New York, NY, USA.
School of Public Health, University of the Western Cape, Cape Town, South Africa.

Carl Lombard (C)

Biostatistics Unit, South African Medical Research Council, Cape Town, South Africa.
School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.

Duduzile Faith Nsibande (DF)

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Thu-Ha Dinh (TH)

Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Center for Global Health, Atlanta, GA, USA.

Vuyolwethu Magasana (V)

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.

Mary Mogashoa (M)

US Center for Disease Control and Prevention, Pretoria, South Africa.

Ameena Ebrahim Goga (AE)

Health Systems Research Unit, South African Medical Research Council, Cape Town, South Africa.
Department of Paediatrics, University of Pretoria, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH